Functional impact of Nicotinamide Riboside on patients with A-T

We are delighted to announce the commencement of a new A-T research study on 1st September 2024 at Leiden University Medical Center, Netherlands.

This is the first of 5 studies comprising the 2024 A-T Global Alliance $2.5M Grant Round funded by Action for A-T (UK), AEFAT (Spain) and BrAshA-T.

The 36-month, $485,000 project will be led by Dr Mirjam van der Burg. Read more

It's Time to Shelve the Shaver and Grow a Beard!

Winter is here which means it's time for the Annual Beard Up Boys fundraiser.

Register to grow a beard throughout winter (June - August) and ask family, friends and colleagues to generously sponsor you for a great cause.

Commencement of Triheptanoin Open Label Phase

The analysis of the Triheptanoin Phase 2 Trial was published at the end of 2023 highlighting that patients demonstrated statistically and clinically meaningful improvements.

This has paved the way for the next step of the trial, the Open Label Phase which commenced in February 2024 (restricted to Australian patients).

During this 12-month phase, patients will continue the use of triheptanoin without placebo. This will also lay the groundwork for an international Phase 3 Trial subsequent to the Open Label Phase. Read more